{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.15","value":"-6.6"},{"groupId":"OG001","spread":"5.66","value":"-8.4"},{"groupId":"OG002","spread":"6.48","value":"-7.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"73"}],"units":"Participants"}],"description":"Maximum decrease in LVEF measures is the change from baseline at worst treatment value. LVEF is measured as percentage.","dispersionType":"Standard Deviation","groups":[{"description":"5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.","id":"OG000","title":"T+P Concomitant Anthracycline-based Chemotherapy"},{"description":"FEC every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.","id":"OG001","title":"T+P Sequential Anthracycline-based Chemotherapy"},{"description":"Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.","id":"OG002","title":"T+P Concomitant Non-Anthracycline Chemotherapy"}],"paramType":"MEAN","populationDescription":"Safety analysis population included all randomized participants who received treatment. Number of participants analyzed is total number of participants evaluable.","reportingStatus":"POSTED","timeFrame":"From baseline up to approximately 3.5 years","title":"Safety: Maximum Decrease in Left Ventricular Ejection Fraction (LVEF) Measures","type":"SECONDARY","unitOfMeasure":"percentage (ejection fraction)"}